SHR-1210 a Novel Anti-pd-1 Antibody, in Combination With BP102,a Biosimilar of Bevacizumab, and XELOX, (Oxaliplatin Plus Capecitabine) in Patient With Metastatic Colorectal Cancer: a Single-arm, Open Label, Multi-center, Phase II Study
Phase of Trial: Phase II
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Camrelizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 08 May 2019 Status changed from recruiting to discontinued.
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 New trial record